SCHEMBL3031111

SCHEMBL3031111

NCCCNCCCCNc1ccc([N+](=O)[O-])c2nonc12

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GSTM2 P28161 1/20 0.70
▸ HRH3 Q9Y5N1 2/20 0.62
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ USP2 O75604 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ RECQL P46063 1/20 0.56
▸ MIF P14174 1/20 0.53
▸ KAT2B Q92831 5/20 0.51
▸ IDO1 P14902 3/20 0.50
▸ S1PR1 P21453 2/20 0.50
▸ S1PR3 Q99500 2/20 0.50
▸ S1PR5 Q9H228 2/20 0.50
▸ MYC P01106 1/20 0.50
▸ S1PR4 O95977 1/20 0.50
▸ PSMD14 O00487 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12939051 0.99 GSTM2 (0.69) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL12387644 0.95 GSTM2 (0.73) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL12939052 0.94 GSTM2 (0.75) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL19690834 0.93 GSTM2 (0.77) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL2420517 0.93 GSTM2 (0.77) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL8429536 0.87 GSTM2 (0.68) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL3014278 0.85 GSTM2 (0.63) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL17896474 0.84 GSTM2 (0.67) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL30581563 0.83 GSTM2 (0.74) GSTM2HRH3MEN1KMT2AUSP2
SCHEMBL19400408 0.82 GSTM2 (0.77) GSTM2HRH3MEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183230-B9 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PF MEDICAMENT (FR) 2015-09-02 — — EP claimed
EP-2183230-B1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PF MEDICAMENT (FR) 2013-11-13 — — EP claimed
US-8569011-B2 Fluorescent derivatives of polyamines, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumors PIERRE FABRE MEDICAMENT (FR) 2013-10-29 — — US claimed
US-20120252059-A1 FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS ANNEREAU JEAN-PHILIPPE (FR) 2012-10-04 — — US claimed
US-20100202975-A1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS PIERRE FABRE MEDICAMENT (FR) 2010-08-12 — — US claimed
EP-2183230-A1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS Pierre Fabre Medicament (FR) 2010-05-12 — — EP claimed
WO-2009013360-A9 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PIERRE FABRE MEDICAMENT (FR) 2010-02-18 — — WO claimed
WO-2009013360-A1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PIERRE FABRE MEDICAMENT (FR) 2009-01-29 — — WO claimed
EP-2183230-B9 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PF MEDICAMENT (FR) 2015-09-02 — — EP disclosed
EP-2183230-B1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PF MEDICAMENT (FR) 2013-11-13 — — EP disclosed
US-8569011-B2 Fluorescent derivatives of polyamines, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumors PIERRE FABRE MEDICAMENT (FR) 2013-10-29 — — US disclosed
US-20120252059-A1 FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS ANNEREAU JEAN-PHILIPPE (FR) 2012-10-04 — — US disclosed
US-20100202975-A1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS PIERRE FABRE MEDICAMENT (FR) 2010-08-12 — — US disclosed
EP-2183230-A1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS Pierre Fabre Medicament (FR) 2010-05-12 — — EP disclosed
WO-2009013360-A9 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PIERRE FABRE MEDICAMENT (FR) 2010-02-18 — — WO disclosed
WO-2009013360-A1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS PIERRE FABRE MEDICAMENT (FR) 2009-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100202975-A1 NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS SRM, SMOX, SLCO2B1 GSTM2 3247/4885HRH3 91/4885MEN1 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback